Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Myc Proto Oncogene Protein (MYC) protein is a transcription factor that activates the expression of many genes through binding enhancer box sequences and recruiting histone acetyltransferases. It also acts as a transcriptional repressor.
The MYC pipeline market research report provides comprehensive information on the MYC targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, the latest news as well as press releases. Additionally, the report provides an overview of key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics development with respective active and dormant or discontinued projects.
Key Therapy Areas in the MYC Pipeline Products Market
The key therapy area in the MYC pipeline products market is oncology.
Key Mechanisms of Action in the MYC Pipeline Products Market
The key mechanism of action in the MYC pipeline products market is Myc Proto Oncogene Protein Inhibitor.
Key Routes of Administration in the MYC Pipeline Products Market
The key routes of administration in the MYC pipeline products market are intravenous and oral.
MYC Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the MYC Pipeline Products Market
The key molecule types in the MYC pipeline products market are small molecule, oligonucleotide, recombinant peptide, synthetic peptide, and peptide.
MYC Pipeline Products Market Analysis by Molecule Types
For more molecule type insights, download a free report sample
Major Companies in the MYC Pipeline Products Market
Some of the major companies in the MYC pipeline products market are Anima Biotech Inc, Arrakis Therapeutics Inc, Arvinas Inc, Biogenera SpA, Ceptur Therapeutics Inc, Cothera Bioscience Pty Ltd, Erasca Inc, Escend Pharmaceuticals Inc, Gibson Oncology LLC, and Kintor Pharmaceutical Ltd.
MYC Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
MYC Pipeline Products Market Report Overview
Key Therapy Areas | Oncology |
Key Mechanisms of Action | Myc Proto Oncogene Protein Inhibitor |
Key Routes of Administration | Intravenous and Oral |
Key Molecule Type | Small Molecule, Oligonucleotide, Recombinant Peptide, Synthetic Peptide, and Peptide |
Major Companies | Anima Biotech Inc, Arrakis Therapeutics Inc, Arvinas Inc, Biogenera SpA, Ceptur Therapeutics Inc, Cothera Bioscience Pty Ltd, Erasca Inc, Escend Pharmaceuticals Inc, Gibson Oncology LLC, and Kintor Pharmaceutical Ltd |
Scope
- The report provides a snapshot of the global therapeutic landscape for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)
- The report reviews Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing, and collaboration details & other developmental activities
- The report reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics and enlists all their major and minor projects
- The report assesses Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews the latest news and deals related to Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Identify and understand the targeted therapy areas and indications for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Arrakis Therapeutics Inc
Arvinas Inc
Biogenera SpA
Ceptur Therapeutics Inc
Cothera Bioscience Pty Ltd
Erasca Inc
Escend Pharmaceuticals Inc
Gibson Oncology LLC
Kintor Pharmaceutical Ltd
Kronos Bio Inc
MecRx Pty Ltd
Omega Therapeutics Inc
OncoViRx LLC
Origenis GmbH
Peptomyc SL
PYC Therapeutics Ltd
Recursion Pharmaceuticals Inc
Sapience Therapeutics Inc
SyntheX Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas in the MYC pipeline products market?
The key therapy area in the MYC pipeline products market is oncology.
-
What are the key mechanisms of action in the MYC pipeline products market?
The key mechanism of action in the MYC pipeline products market is Myc Proto Oncogene Protein Inhibitor.
-
What are the key routes of administration in the MYC pipeline products market?
The key routes of administration in the MYC pipeline products market are intravenous and oral.
-
What are the key molecule types in the MYC pipeline products market?
The key molecule types in the MYC pipeline products market are small molecule, oligonucleotide, recombinant peptide, synthetic peptide, and peptide.
-
Which are the major companies in the MYC pipeline products market?
Some of the major companies in the MYC pipeline products market are Anima Biotech Inc, Arrakis Therapeutics Inc, Arvinas Inc, Biogenera SpA, Ceptur Therapeutics Inc, Cothera Bioscience Pty Ltd, Erasca Inc, Escend Pharmaceuticals Inc, Gibson Oncology LLC, and Kintor Pharmaceutical Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.